Clinical Trials Logo

Kidney Cancer clinical trials

View clinical trials related to Kidney Cancer.

Filter by:

NCT ID: NCT00620295 Completed - Breast Cancer Clinical Trials

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Start date: March 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and gemcitabine in treating older patients with advanced solid tumors.

NCT ID: NCT00617799 Completed - Kidney Cancer Clinical Trials

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

Start date: October 2, 2007
Phase:
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers that predict response to high-dose aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.

NCT ID: NCT00606632 Completed - Clinical trials for Renal Cell Carcinoma

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

NCT ID: NCT00588913 Completed - Metastatic Cancer Clinical Trials

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may help the laboratory-treated white blood cells stay in the body longer. Drugs used in chemotherapy, such as zoledronic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cellular adoptive immunotherapy together with interleukin-2 and zoledronic acid may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cellular adoptive immunotherapy together with aldesleukin and zoledronic acid and to see how well it works in treating patients with stage IV kidney cancer and lung metastases.

NCT ID: NCT00541008 Completed - Kidney Cancer Clinical Trials

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Start date: September 5, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works as first-line therapy in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer.

NCT ID: NCT00537056 Completed - Clinical trials for Carcinoma, Renal Cell

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Start date: October 2007
Phase: N/A
Study type: Interventional

To learn whether FDG PET/CT and DCE MRI are better predictors of response to therapy than the current standard of care (CT or MRI).

NCT ID: NCT00534001 Completed - Lung Cancer Clinical Trials

Bupropion in Helping Adults Stop Smoking

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking. PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.

NCT ID: NCT00514215 Completed - Lung Cancer Clinical Trials

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cryotherapy together with GM-CSF works in treating patients with lung metastases or primary lung cancer.

NCT ID: NCT00505310 Completed - Kidney Cancer Clinical Trials

Biobehavioral Effects of Emotional Expression in Cancer

Start date: August 21, 2002
Phase: N/A
Study type: Interventional

The proposed study will assess the psychological and physiological benefits of an emotional expression intervention in patients with renal cancer. Patients will be randomly assigned to an emotional expression writing group or to a neutral writing group. This study will also evaluate the extent to which psychosocial factors mediate the intervention program and predict patients' recovery and adjustment to treatment. Potential mediators include level of cognitive processing, social networks/interactions, and sense of coherence and ability to find meaning in the illness experience. Specific objectives of the proposed research are: - To evaluate an emotional expression intervention in patients with renal cancer. Researchers will determine the extent to which an emotional expression writing-based intervention enhances adjustment during the first 12 months following diagnosis and treatment. Dimensions of adjustment will be assessed by examining indices of QOL, mental health, and stress (subjective symptoms of distress, perceived stress, and mood). - To determine the effects of an emotional expression writing-based intervention on immune function. The immune measures assessed in this study will include both general and autologous tumor-specific immune responses including cytotoxicity to K562 target cells; cytotoxicity to autologous tumor target cells; and functional assessment of type-1 and type-2 cytokines using autologous tumor and polyclonal stimulants. - To identify the psychosocial processes underlying the efficacy of the intervention.

NCT ID: NCT00498966 Completed - Kidney Cancer Clinical Trials

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: - To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor - To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor